氨甲环酸在创伤性脑损伤患者中的应用:纤溶关闭患者是否获益?
该回顾性队列纳入3家创伤中心394例就诊时行TEG的TBI患者,按LY30分为纤溶关闭(<0.5%)、生理性(0.5–7.7%)和纤溶亢进(>7.7%)。纤溶关闭占72%,其未校正死亡率16% vs 非关闭9.2%(P=0.090),校正后无独立关联(OR 1.37,95%CI 0.62–3.05)。在纤溶关闭亚组,接受TXA者死亡率12%(24/196)vs 未接受者24%(21/89),校正后OR 0.36(95%CI 0.16–0.77);非关闭亚组无差异(校正OR 0.96,95%CI 0.16–5.78)。作者结论支持早期给TXA,不因等待TEG解读而延迟。
要点
- TBI伴纤溶关闭(LY30<0.5%)者接受TXA后校正死亡风险更低:OR 0.36(95%CI 0.16–0.77),未校正死亡率12% vs 24%。
- 纤溶关闭本身并非独立死亡危险因素:校正后OR 1.37(95%CI 0.62–3.05),未校正死亡率16% vs 9.2%(P=0.090)。
- 非纤溶关闭患者中TXA未见死亡率差异:9.6% vs 8.3%(P=1.00),校正OR 0.96(95%CI 0.16–5.78)。
- 作者据此支持早期给予TXA,不应为等待TEG解读而延迟治疗。
- 证据等级为治疗/管理Level IV,为回顾性三中心队列,结论需前瞻性验证。
适用人群与场景
- 三家附属创伤中心就诊时接受TEG的TBI患者,平均年龄64±21岁,56%为平地跌倒,74%为轻度TBI。
- 排除:TEG前已接受TXA、入院后>3小时才给TXA、GCS=3且瞳孔无反应或损伤不可存活者。
诊断标准与关键阈值
- 按TEG的LY30分层:纤溶关闭LY30<0.5%,生理性0.5–7.7%,纤溶亢进>7.7%。
处置流程与药物剂量
- 原文未提及具体TXA剂量、给药途径、频次或疗程。
- 作者结论支持早期给予TXA,不因等待TEG解读而延迟治疗。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 回顾性队列,3家创伤中心,394例TBI患者;纤溶关闭285例(72%)、生理性107例(27%)、纤溶亢进2例(0.5%)。
- 主要终点为28天内全因死亡(院内或临终关怀机构);纤溶关闭未校正死亡率16% vs 非关闭9.2%(P=0.090),校正年龄、ISS、GCS、多腔隙颅脑损伤、神经外科手术和TXA后OR 1.37(95%CI 0.62–3.05)。
- 纤溶关闭亚组:TXA者死亡率12%(24/196)vs 未用TXA者24%(21/89),P=0.015;校正年龄、ISS、GCS、多腔隙颅脑损伤和神经外科手术后OR 0.36(95%CI 0.16–0.77)。
- 非纤溶关闭亚组:TXA者9.6%(7/73)vs 未用TXA者8.3%(3/36),P=1.00;校正后OR 0.96(95%CI 0.16–5.78)。
证据类型、等级与局限
- 证据类型:回顾性队列研究;原文标注证据等级为治疗/管理Level IV。
- 局限:回顾性设计、三中心、样本量有限(纤溶亢进仅2例),TXA剂量与给药方案原文未描述,需前瞻性验证。
对床旁实践的改变
- 对TBI患者可按原文结论早期给予TXA,不因等待TEG解读而延迟;该结论主要来自纤溶关闭(LY30<0.5%)亚组的校正结果。
- 非纤溶关闭患者中TXA未见死亡率获益(校正OR 0.96,95%CI 0.16–5.78),不能据本文扩大获益人群。
- 原文未提供TXA剂量与给药方案,不能将研究中的用药方案当作通用推荐;证据为Level IV回顾性队列,不能据此改变标准流程以外的决策。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Tranexamic acid (TXA) is widely used in patients with traumatic brain injury (TBI). However, its pharmacology suggests differences in effectiveness should exist based on fibrinolytic phenotype, particularly fibrinolytic shutdown. This study examined whether fibrinolytic shutdown is associated with increased mortality in TBI and whether TXA retains its benefit in this subgroup.
METHODS: This retrospective cohort study included TBI patients who had thromboelastography (TEG) upon presentation at three affiliated trauma centers. Patients were excluded if they received TXA before TEG, had TXA >3 hours postadmission, Glasgow Coma Score (GCS)=3 and a nonreactive pupil or a nonsurvivable injury. The primary endpoint was all-cause mortality, either in-hospital or in-hospice, up to 28 days. Patients were stratified by fibrinolytic phenotype: shutdown (LY30<0.5%), physiologic (0.5-7.7%), or hyperfibrinolytic (>7.7%) and TXA receipt. Univariate and multivariate analyses were performed.
RESULTS: Of 394 patients (mean age 64±21 y; 56% ground-level falls; 74% mild TBI), fibrinolytic shutdown predominated [72% (n=285)], followed by physiologic [27% (n=107)], and hyperfibrinolysis [0.5% (n=2)]. Unadjusted mortality was 16% with shutdown versus 9.2% without ( p =0.090). After controlling for age, ISS, GCS, multicompartmental head injury, neurosurgical intervention, and TXA, there was no association between shutdown phenotype and mortality [OR (95% CI) =1.37 (0.62-3.05)]. In patients with fibrinolytic shutdown, unadjusted mortality was lower in patients who received TXA [12% (24/196) vs. 24% (21/89), p =0.015]. After controlling for age, ISS, GCS, multicompartmental head injury, and neurosurgical intervention, mortality remained lower [OR (95% CI)=0.36 (0.16-0.77)]. In patients without fibrinolytic shutdown, no difference in mortality was noted [TXA, 9.6% (7/73) vs. no TXA, 8.3% (3/36), p =1.00]. These results did not change after controlling for the above confounders [OR (95% CI)=0.96 (0.16-5.78)].
CONCLUSIONS: TXA remained associated with lower mortality in TBI patients with fibrinolytic shutdown, despite pharmacologic expectations. Fibrinolytic shutdown was not independently associated with higher mortality. These findings support early TXA administration without delaying treatment for TEG interpretation.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level IV.
参考来源
- Barletta JF, Lim H, Sucher JF, et al. Tranexamic acid in patients with traumatic brain injury: Is there benefit in patients with fibrinolytic shutdown? J Trauma Acute Care Surg. 2026. PMID: 42441910. doi:10.1097/TA.0000000000005066
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。